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Care of men with cancer-predisposing BRCA variants
Rachel Horton, 1 , 2 Paul Pharoah, 3 Judith Hayward, 4 , 5 Anneke Lucassen1 , 6
What you need to know
• Men and women are equally likely to inherit or pass
on a cancer-predisposing BRCA variant—family history
of cancers needs to encompass both sides of the
family
• Men with cancer-predisposing BRCA variants have an
increased risk of developing breast cancer and are
advised to be breast aware
• Men with cancer-predisposing BRCA2 variants have
an increased risk of developing aggressive prostate
cancer (men with cancer-predisposing BRCA1 variants
may also have an increased risk); it is not yet known
whether prostate specific antigen screening reduces
mortality in men with cancer-predisposing BRCA
variants
• The European Association of Urology recommends
that PSA screening is offered to men with
cancer-predisposing BRCA2 variants from 40 years of
age after discussion of the risks and benefits
Around one in 260 men (~0.4%) inherits a
cancer-predisposingBRCAvariant that increases their
risk of developing prostate, pancreatic, and breast
cancer and may affect the health of their family.1 2
Most of these men are currently unaware that they
have a cancer-predisposing BRCA variant, but as
genetic testing becomes more common, more men
will need medical advice about what having such a
variant means for them and their families.
Men are just as likely as women to have a
cancer-predisposing BRCA variant, but many people
perceive these variants as only being relevant to
women. Paradoxically, this could lead to women at
very high risk of breast and ovarian cancer missing
out on screening and risk-lowering treatment despite
a concerningpaternal familyhistory. Cliniciansmight
also be less attuned to paternal family history of
cancer in assessing women’s breast cancer risk.3 This
practice pointer covers what cancer-predisposing
BRCA variants are, who might be tested; and what
health issues men and their clinicians need to know
about. We refer to men, but the article also applies
to transwomen and some non-binary people.
Whatarecancer-predisposingBRCAvariants?
BRCA1 and BRCA2 are tumour suppressor genes that
code forDNA repair proteins. Certain variants in these
genespredispose to cancer (primarily breast, ovarian,
prostate, and pancreatic, and for BRCA2 possibly
melanoma4) (fig 1). The predisposition to cancer is
inherited in an autosomal dominant way, ie, each
and every time a person with a cancer-predisposing
BRCA variant has a child, they have a 1 in 2 or 50:50
chance of passing their BRCA variant on to the child.
This is regardless of whether parent or child is male
or female.
Many men and some women with
cancer-predisposingBRCAvariantswill neverdevelop
an associated cancer (fig 1). The cancer risks
associated with cancer-predisposing BRCA variants
are modified by lifestyle factors and other inherited
genetic variants. Polygenic risk scores (calculated by
looking at multiple common genetic variants across
the genome, each with a tiny individual effect) show
potential to refine cancer risk predictions for people
with cancer-predisposing BRCA variants, but cannot
remove uncertainty as to whether a given patient will
or will not develop cancer.10
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Fig 1(a) | Risk of ovary, prostate, and pancreatic cancer associated with cancer-predisposing BRCA variants (cumulative cancer risks are shown on different scales).
Cancer-predisposing BRCA1 variants increase the risk of pancreatic cancer (relative risk 4.11)5 but data are emerging, and cumulative risk figures are not readily available.
Data on ovary cancer from Kuchenbaecker et al 20176; prostate from Nyberg et al 2020,7and pancreatic cancer from van Asperen et al 2005.8 Population data are for
England and Wales 2016 (Office for National Statistics)
Fig 1(b) | Risk of female and male breast cancer associated with cancer-predisposing BRCA variants. Data from Tai et al 20079 Population data are for England and Wales
2016 (Office for National Statistics)
Describing genetic variants
Various terms are used to describe genetic variants that increase risk of
disease. As with many medical terms, different people might understand
different things by the same term.
The term “mutation” is often used in patient leaflets, patient support
forums, and in UK school curriculums. However, some find the term
offensive36 and it is technically incorrect since it suggests the mutation
has happened in that person. “Faulty gene” is also often used in patient
resources, and a 2007 Australian survey indicated that this term was
most preferred by the general community and by patients recruited via
cancer genetics clinics.37
“Pathogenic” or “likely pathogenic variant” is commonly used in
laboratory genetic reports. People are increasingly familiar with the term
“variant” in the context of covid-19, but “pathogenic” may be less well
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understood by people without a healthcare background, so
“disease-causing” is sometimes used instead. However, this in turn may
give the false impression that everyone with a “disease-causing BRCA
variant” will inevitably develop an associated cancer. Other terms in
common use include: “disease-risk variant,” “genetic risk factor,”
“disease-predisposing variant,” “loss-of-function variant,” “gene
alteration,” “gene change” and for people with cancer-predisposing BRCA
variants, “BRCA carriers.” Importantly there are also many variants in
BRCA1 and BRCA2 which are not associated with cancer risks.
In discussion with our hospital Patient and Public Involvement group it
was evident that different people found different terms most helpful. We
use the term “cancer-predisposing variant” here as it is informative and
technically accurate, but whatever term you use to describe
cancer-predisposing BRCA variants, key messages to convey are
• variants are very likely to be inherited rather than to have happened
for the first time in the tested person
• variants are risk factors for particular cancers rather than certainties
that they will develop.
Thousands of different variants within the BRCA1 and BRCA2 genes
have been described, and classifying which are benign and which
increase cancer risk canbe challenging.11 Asmoredata are gathered,
classifications may shift. For example a Canadian laboratory
examined the BRCA variants they identified over a five year period
and found that 12% were reclassified (75% of these were
downgraded—ie, they arenow thought to be less likely topredispose
to cancer than they were when the BRCA test was originally done).12
Diagnostic tests involve sequencing of BRCA1 and BRCA2 (and
perhaps other genes, eg, PALB2), aiming to detect any variant
present that might increase cancer risk.
Howwould aman find out that he has a
cancer-predisposing BRCA variant?
In the UK, diagnostic BRCA testing is currently offered to people
with a 10% or greater chance of having a cancer-predisposing BRCA
variant.13 Most diagnosticBRCA tests are done for women, but some
menwill find out theirBRCA status via this route, asmenwith breast
cancer at any age are eligible to be tested,14 and some men with
prostate or pancreatic cancer may have testing to determine
eligibility for poly(ADP-ribose) polymerase (PARP) inhibitors (often
in the context of clinical trials).
More commonly, men are offered targeted BRCA testing after a
cancer-predisposing BRCA variant is identified in their family.
Usually this will be predictive testing (ie, the man has no personal
medical history suggestive of a cancer-predisposingBRCA variant),
although occasionally it may be explanatory (eg, in men known to
have prostate cancer). The laboratory would need details of the
specific cancer-predisposing BRCA variant in the man’s family in
order to test for it (eg, a genetic report from an affected family
member) and such targeted testing would not detect any other
cancer-predisposing variants.
Around 1.5% of patients with prostate cancer have a
cancer-predisposingBRCA variant,15 but a personal medical history
of prostate cancer is not an indication for diagnostic BRCA testing
in the UK. However, for patients with younger-onset, aggressive
disease, a thorough family history can explore the possibility of a
familial cancer-predisposing BRCA variant. A family history that
includes, for example, bilateral breast cancer, male breast cancer,
or multiple people affected by breast or ovarian cancer (especially
at younger ages), probably warrants discussion with your local
genetics service.
Some men might access BRCA testing outside standard clinical
pathways, such as through direct-to-consumer genetic testing or
research studies.16 These tests are of variable quality and scope,
and further scrutiny may be needed to confirm that the variant is
really present or really represents a risk.17
Case studies
Cancer-predisposingBRCAvariants increase the riskofaggressive
prostate cancer
Rahul is a 40 year old man who had a test via a genetics clinic for the
cancer-predisposing BRCA2 variant identified in his aunt. Rahul was
also found to have the BRCA2 variant and is concerned about
developing prostate cancer. He books an appointment with you to
discuss prostate specific antigen (PSA) screening.
Men with cancer-predisposing BRCA2 variants like Rahul have an
increased risk of prostate cancer: a recent meta-analysis indicated
an odds ratio of 2.64,15 and a large prospective cohort study in the
UK and Ireland found a 27% absolute risk of developing prostate
cancer by age 75, rising to 60% by age 857 (for comparison,
population risk by age 85 is 16% in England and Wales based on
Office forNational Statistics 2016data).Whenprostate cancer occurs
in a man with a cancer-predisposing BRCA2 variant, it tends to be
more aggressive.18The evidence has been inconsistent regarding
the impact of cancer-predisposingBRCA1variants onprostate cancer
but a subtler effect is probable, with an odds ratio of 1.35,15 and the
relative risk increase is higher at younger ages.19 20
The IMPACT study is an ongoing international prospective cohort
study of more than 3000 men to examine the use of PSA screening
in men with cancer-predisposing BRCA variants. Based on interim
results, the researchers recommend that men with
cancer-predisposing BRCA2 variants are offered systematic PSA
screening,21 and this could be considered for Rahul. This is because
after three years of PSA screening, men with cancer-predisposing
BRCA2variants proved tohaveahigher incidenceof prostate cancer,
were younger at diagnosis, and were more likely to have clinically
significant tumours. The positive predictive value of a PSA >3.0
ng/mLwashigher inmenwith cancer-predisposingBRCA2 variants
than in controls (31% versus 18%).
Discuss with Rahul the pros and cons of PSA screening and be clear
about the current limits of medical knowledge. It would be
appropriate to include in this discussion that if a prostate cancer
does develop in a man with a cancer-predisposing BRCA2 variant,
it is more likely to be clinically significant. Interim analysis from
the IMPACT study shows that after four screening rounds (annual
PSA) for men aged 55-69 with cancer-predisposing BRCA2 variants,
you would expect to detect one clinically significant prostate cancer
for every 13 men screened.21 The European Association of Urology
recommends offering PSA based prostate cancer screening to men
with cancer-predisposingBRCA2variantswhohavebeencounselled
on the potential risks and benefits of screening from the age of 40
although they do not specify a screening interval.22 It is not yet
known whether PSA screening will reduce mortality from prostate
cancer in men with cancer-predisposing BRCA2 variants.
Research is ongoing as to the role of PSA screening for men with
cancer-predisposing BRCA1 variants: an interim analysis found no
differences in age or tumour characteristics between men with
cancer-predisposing BRCA1 variants and controls.21
3the bmj | BMJ 2021;375:n2376 | doi: 10.1136/bmj.n2376
PRACTICE
Breast awareness is important formenwith cancer-predisposing
BRCA variants
Jakob is a 50 year old man who books an appointment to discuss a
painless “cyst” near his left nipple that he noticed several months
ago. On examination, you notice that he has an inverted nipple and
ipsilateralaxillary lymphadenopathy. When you ask about his family
history, he tells you that his father died of prostate cancer in his 60s.
Men with cancer-predisposing BRCA variants have an increased
lifetime risk of developing breast cancer: 8.3% for BRCA2 and 1.8%
for BRCA1, compared with 0.1% in the general population.9 As in
women, breast cancer inmenmost commonlypresents as apainless
mass. Although nipple involvement tends to be seen earlier due to
the smaller amount of breast tissue,23 male breast cancer is often
diagnosed at an advanced stage.23 Men with cancer-predisposing
BRCA variants are at higher risk of developing breast cancer, but
any man with symptoms of breast cancer warrants urgent referral
to abreast clinic in the samewaywomenpresentingwith concerning
symptoms would be referred, regardless of BRCA status.
Evidence regarding breast cancer characteristics in men with
cancer-predisposingBRCAvariants is limited. Twostudies analysing
tumour grading, staging, and receptor status in men with breast
cancer suggest that cancer-predisposing BRCA2 variants are
associated with more aggressive cancers.24 25
Evidence is also lacking on breast cancer screening in men with
cancer-predisposing BRCA variants, and practice varies.26 In the
UK, men with cancer-predisposing BRCA variants are advised to be
breast aware, ie, to know how their breasts usually look and feel,
and seek medical advice if they notice changes or have any
concerns.13 Men might be more likely to delay seeking care for a
new breast lump, perhaps waiting until the lump becomes painful
or changes the overlying skin. A study in Hong Kong of men with
breast cancer found that median duration from symptoms to first
medical consultation was 12.4 months, and 84% were not aware
(before their diagnosis) that breast cancer could occur in men.27
Raising this issue may be challenging, particularly as resources
promoting breast awareness are mainly aimed at women.28 Our
hospital Patient and Public Involvement group highlighted some
of the issues men might face during and after receiving a breast
cancer diagnosis, for example being the only man in the waiting
room for appointments.
Patientsmaybeunaware that cancer-predisposingBRCAvariants
can be passed on by men
Harry is a 55 year old man whom you see regularly for diabetes
management. At the end of an appointment discussing his blood
sugars, he mentions that his sister in Australia recently told him that
she “has BRCA” and that he should get tested. You ask how he feels
about this, and he says he can’t see the point because “isn’t BRCA a
female thing?” Harry has two daughters in their 30s.
Because cancer-predisposing BRCA1 and BRCA2 variants are
notorious for increasing lifetime risk of breast and ovarian cancer
in women, there is a common misperception that
cancer-predisposing BRCA variants themselves only occur in
women.29 Cancer-predisposing BRCA variants are just as common
in men as they are in women but are less likely to be detected
because they are less likely to cause a cancer that prompts genetic
testing.
Explain that men and women inherit these genetic variants in the
same way: that any child of a parent with a cancer-predisposing
BRCA variant has a 50:50 chance of inheriting that variant. This
would include Harry’s children if Harry also has the BRCA variant
identified in his sister.
For some men, concern for the health of existing or potential
daughters or granddaughters is a key motivation for seeking BRCA
testing.29 30 In contrast, sometimes men are reluctant to have BRCA
testing because they are concerned about potentially havingpassed
a cancer-predisposingBRCA variant on to their children. Theymight
prefer not to know than to have this possibility confirmed. It may
help to remind them that the cancer-predisposing BRCA variant has
likely been in their family for generations andwhether they inherited
or passed it on is outside their control. However, being tested for it
might guide medical care for them and their children, for example
by informing choices about cancer screening (fig 2).
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Fig 2 | A family learning about BRCA
Occasionally, men decide that they do not wish to be tested for a
cancer-predisposing BRCA variant found in their family. It would
still be appropriate and important to refer their adult, first degree
relatives (eg, siblings or children) to clinical genetics specialists if
they wish, even if testing them might (indirectly) reveal that the
man has the cancer-predisposing BRCA variant. Clinical genetic
services are skilled at counselling patients through difficult
psychosocial and ethical issues such as this scenario (box 2).
Box 2: Ethical issues
Identifying a cancer-predisposing BRCA variant may raise various ethical
issues, for example:
Sharing genetic information within families
Family members may benefit from testing for the cancer-predisposing
BRCA variant. What if the person in whom it was identified finds it difficult
to tell their family about the variant, or chooses not to? Health
professionals may sometimes need to balance the competing tensions
of patient confidentiality with the interests others have in knowing about
their risks.
Decisions around termination of pregnancy owing to adult onset
conditions
People with cancer-predisposing BRCA variants have a substantially
increased risk of developing certain cancers, but these are adult-onset
and some people with such variants will never develop cancer.
Shifting understanding of what particular genetic variants mean
Classifying BRCA variants as benign or cancer-predisposing is technically
challenging. Over time, new evidence may shift our understanding of
what a particular variant means (eg, it may become clear that a variant
thought to predispose to cancer is actually benign, or vice versa). How
should clinicians respond when this happens?
Men with cancer-predisposing BRCA variants have an increased
risk of developing pancreatic cancer
Simon is a 50 year oldmanwho hada test two years ago via a genetics
clinic for the cancer-predisposing BRCA2 variant identified in his
sister. Simonwas also found to have the BRCA2 variant anddiscussed
his increased risk of prostate and pancreatic cancer with a genetic
counsellor at the time. Last week Simon’s friend was diagnosed with
pancreatic cancer. Simon is now more concerned about his risk of
pancreatic cancer and books an appointment to discuss it with you.
People with cancer-predisposing BRCA variants have an increased
risk of developingpancreatic cancer: a retrospective cohort analysis
of a high-risk breast cancer family registry from the US, Canada,
and Australia estimated that pancreatic cancer risk is five to six
times higher than population risk for people with
cancer-predisposing BRCA2 variants and around four times higher
for peoplewith cancer-predisposingBRCA1variants.5 Unfortunately,
pancreatic cancer is challenging to screen for and is often advanced
by the time symptomsdevelop.Guidance from theNational Institute
for Health and Care Excellence (2018) on pancreatic cancer
recommended that people with cancer-predisposingBRCA variants
and one or more first degree relatives with pancreatic cancer have
surveillance (magnetic resonance imaging/magnetic resonance
cholangiopancreatography or endoscopic ultrasound),31 but this
was challenged by the UK Cancer Genetics Group as being
premature.32 Instead, the group recommended that pancreatic
cancer screening should only be offered within the context of
research studies such as EUROPAC.33 In practice, pancreatic cancer
screening is generally considered on a case-by-case basis for people
with cancer-predisposing BRCA variants if they also have a family
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history of pancreatic cancer. Screening as part of a research study
might be a possibility for Simon—your local genetics service may
be able to signpost towards this.
Around 6-7% of people with metastatic pancreatic cancer have a
germline cancer-predisposingBRCA variant.34 Increasingly, people
withpancreatic cancer are offereddiagnosticBRCA testing to inform
treatment plans. Cancer cells with cancer-predisposing BRCA
variants already have impaired DNA repair and are heavily reliant
on DNA repair pathways involving PARP, so are particularly
vulnerable to PARP inhibitors. PARP inhibitors may be a treatment
option for peoplewith a germline cancer-predisposingBRCA variant
who have breast, ovarian, pancreatic, or prostate cancer (often in
the context of clinical trials).35
Education into practice
• Do you ask about paternal as well as maternal family history when
assessing a patient’s risk of breast cancer?
• What questions might you ask if a man tells you he doesn’t want
testing for the cancer-predisposing BRCA variant found in his family?
• When did you last ask a man about his family history of breast and
ovarian cancer?
How patients were involved in the creation of this article
We spoke with men from the Patient and Public Involvement group at
University Hospitals Southampton NHS Foundation Trust to discuss what
prior knowledge men might have about cancer-predisposing BRCA
variants, what information they might want to know after finding that
they had a cancer-predisposing BRCA variant, and what terminology they
might prefer when talking about genetic variants. These discussions
particularly influenced the case study section, the discussion about
expectations in “How would a man find out that he has a
cancer-predisposing BRCA variant?,” and the box “Describing genetic
variants.”
How this article was made
We developed fictitious cases to illustrate common issues that may arise
for men with cancer-predisposing BRCA variants, based on scenarios
encountered by our regional genetics department.
We used PubMed and author research paper archives to search for
information about cancer risks and medical care for men with
cancer-predisposing BRCA variants. We aimed to quote cancer risks
established by large prospective cohort studies. Medical care of men
with cancer-predisposing BRCA variants is under-researched and often
guidelines are lacking—in these cases, we have drawn on our experience
within a UK regional genetics department to aim to reflect UK standard
practice.
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